Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Lawmakers hear competing testimony on establishing a Prescription Drug Affordability Board
Summary
SB 2933 prompted split testimony: supporters with PDAB experience said boards can identify high‑cost drugs and craft evidence‑based reviews; industry and trade groups warned PDABs are unproven, costly, and may not reduce patient out‑of‑pocket costs.
Senate Bill 2933, which would create a Prescription Drug Affordability Board (PDAB), drew a mix of supportive and critical testimony at the Feb. 17 joint committee session.
Courtney Whitlock, who works on prescription‑drug affordability policy and offered testimony in a personal capacity, described operational lessons from Oregon’s PDAB: success…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
